Cowen and Company Reaffirms “Buy” Rating for Voyager Therapeutics Inc. (VYGR)
A number of other research analysts also recently issued reports on VYGR. Stifel Nicolaus started coverage on shares of Voyager Therapeutics in a research report on Thursday, July 14th. They set a buy rating and a $33.00 target price for the company. Piper Jaffray Cos. set a $37.00 target price on shares of Voyager Therapeutics and gave the company a buy rating in a research report on Thursday, August 11th. Wedbush restated an outperform rating and set a $36.00 target price on shares of Voyager Therapeutics in a research report on Thursday, August 11th. Finally, Zacks Investment Research upgraded shares of Voyager Therapeutics from a hold rating to a buy rating and set a $13.00 target price for the company in a research report on Wednesday, October 12th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $26.80.
Voyager Therapeutics (NASDAQ:VYGR) opened at 13.24 on Thursday. The stock’s market cap is $353.88 million. Voyager Therapeutics has a one year low of $8.12 and a one year high of $30.54. The company’s 50-day moving average price is $12.13 and its 200-day moving average price is $12.92.
Hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company acquired a new stake in shares of Voyager Therapeutics during the third quarter valued at about $113,000. Rhumbline Advisers acquired a new stake in shares of Voyager Therapeutics during the third quarter valued at about $126,000. Strs Ohio boosted its stake in shares of Voyager Therapeutics by 531.6% in the second quarter. Strs Ohio now owns 12,000 shares of the company’s stock valued at $131,000 after buying an additional 10,100 shares in the last quarter. KCG Holdings Inc. acquired a new stake in shares of Voyager Therapeutics during the third quarter valued at about $132,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Voyager Therapeutics during the third quarter valued at about $134,000. 39.58% of the stock is owned by institutional investors and hedge funds.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
Receive News & Stock Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related stocks with our FREE daily email newsletter.